Ac Immune Advances Anti-Tau Vaccine ACI-35.030 pour la phase 2 de l'essai.

Published Date: 24 Dec 2023

500 people with preclinical Alzheimer's disease will be randomized to either ACI-35.030 or a placebo for a maximum of four years in the recently announced trial, called ReTain.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

2.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

3.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot